Company Overview of Conatus Pharmaceuticals Inc.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its products include Emricasan, an orally active pan-caspase protease inhibitor, which is in Phase 2 clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post liver transplant clearance of hepatitis C virus infection with sustained viral response, non-alcoholic steatohepatitis, and nonalcoholic fatty liver disease. The company was founded in 2005 and is headquartered in San Diego, California.
16745 West Bernardo Drive
San Diego, CA 92121
Founded in 2005
Key Executives for Conatus Pharmaceuticals Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $460.0K
Co-Founder, Chief Scientific Officer and Executive Vice President of Research & Development
Total Annual Compensation: $325.6K
Executive Vice President of Clinical Development
Total Annual Compensation: $94.0K
Compensation as of Fiscal Year 2014.
Conatus Pharmaceuticals Inc. Key Developments
Conatus Pharmaceuticals Inc. Presents at Stifel Healthcare Conference 2015, Nov-18-2015 11:45 AM
Nov 11 15
Conatus Pharmaceuticals Inc. Presents at Stifel Healthcare Conference 2015, Nov-18-2015 11:45 AM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Steven J. Mento, Co-Founder, Chief Executive Officer, President and Director.
Conatus Pharmaceuticals Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Provides Updates on its Clinical Development Programs
Nov 4 15
Conatus Pharmaceuticals Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, net loss was $6.1 million or $0.31 per basic and diluted share compared with $6.4 million or $0.42 per basic and diluted share for the third quarter of 2014.
For the first nine months of 2015, net loss was $18.1 million or $0.99 per basic and diluted share compared with $17.0 million or $1.10 per basic and diluted share for the first nine months of 2014.
The company provided updates on its clinical development programs. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease and recently reported top-line results from its Phase 2 Portal Hypertension (PH) clinical trial in patients with liver cirrhosis and portal hypertension. Conatus currently has two active Phase 2 clinical trials: POLT-HCV-SVR: in post-orthotopic liver transplant (POLT) recipients with liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy; and Liver Cirrhosis (LC): in patients with liver cirrhosis and Model for End-stage Liver Disease (MELD) scores of 11 to 18. Conatus announced in September 2015 that the PH clinical trial met the following primary endpoints: a) a clinically meaningful and statistically significant change from baseline in HVPG in patients with liver cirrhosis and severe portal hypertension (HVPG 12 mmHg); and b) a statistically significant change from baseline in cleaved Cytokeratin 18 (cCK18), a mechanism-specific biomarker of excessive cell death that contributes to chronic inflammation, in the total evaluable patient population.
Conatus Pharmaceuticals Inc. to Report Q3, 2015 Results on Nov 04, 2015
Oct 28 15
Conatus Pharmaceuticals Inc. announced that they will report Q3, 2015 results at 4:30 PM, US Eastern Standard Time on Nov 04, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|